2.New perspectives of biomarkers for the management of chronic hepatitis B.
Clinical and Molecular Hepatology 2016;22(4):423-431
With recent advances in molecular and genomic investigations, the impact of hepatitis B viral and host factors on the progression of chronic HBV infection has been explored. For viral factors, hepatitis B viral load is a strong predictor for liver disease progression. Hepatitis B viral kinetics appear to be important for successful anti-viral therapy. Serum HBsAg level serves as a complementary marker to viral load for the prediction of HBV-related adverse outcomes in patients with low viral load. In those with low viral load, high serum HBsAg level is associated with higher risks of cirrhosis and HCC. Hepatitis B core-related antigen (HBcrAg) induces host immune responses, and the reduction of the HBcrAg level as well as the increment of total anti-HBc level are significantly associated with favorable outcomes. HBV genotypes (genotype C/D) and mutants (basal core promoter and deletion mutation in pre-S genes) are well known viral genetic markers to predict disease progression. For host factors, serum inflammatory biomarkers have been developed to evaluate the HBV-associated hepatic necroinflammation and fibrosis. Host single nucleotide polymorphism on sodium taurocholate cotransporting polypeptide (NTCP, an HBV entry receptor) may be associated with a decreased risk for cirrhosis and HCC. In conclusion, patients with chronic hepatitis B should be evaluated with relevant viral and host markers to identify those who are at a higher risk of liver disease progression and then receive timely antiviral therapy.
Biomarkers/*blood
;
DNA, Viral/blood
;
Hepatitis B Surface Antigens/blood
;
Hepatitis B e Antigens/blood
;
Hepatitis B virus/genetics
;
Hepatitis B, Chronic/complications/*diagnosis/prevention & control
;
Humans
;
Liver Cirrhosis/etiology
;
Organic Anion Transporters, Sodium-Dependent/genetics
;
Polymorphism, Single Nucleotide
;
Risk Factors
;
Symporters/genetics
3.Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis.
Hye Young JWA ; Yoo Kyung CHO ; Eun Kwang CHOI ; Heung Up KIM ; Hyun Joo SONG ; Soo Young NA ; Sun Jin BOO ; Seung Uk JEONG ; Bong Soo KIM ; Byoung Wook LEE ; Byung Cheol SONG
Clinical and Molecular Hepatology 2016;22(1):183-187
Recent studies suggest that liver cirrhosis is reversible after administering oral nucleos(t)ide analogue therapy to patients with hepatitis B virus (HBV) infection. However, few studies have addressed whether esophageal varices can regress after such therapy. We report a case of complete regression of esophageal varices during entecavir therapy in patients with HBV-related liver cirrhosis, suggesting that complications of liver cirrhosis such as esophageal varices can regress after the long-term suppression of HBV replication.
Abdomen/diagnostic imaging
;
Antiviral Agents/*therapeutic use
;
DNA, Viral/blood
;
Esophageal and Gastric Varices/complications/prevention & control
;
Guanine/*analogs & derivatives/therapeutic use
;
Hepatitis B virus/genetics
;
Hepatitis B, Chronic/complications/*drug therapy/virology
;
Humans
;
Liver Cirrhosis/*diagnosis/etiology
;
Male
;
Middle Aged
;
Polymerase Chain Reaction
;
Ultrasonography
4.Risk Factors for Acute Hepatitis A Infection in Korea in 2007 and 2009: A Case-Control Study.
Joo Youn SEO ; Bo Youl CHOI ; Moran KI ; Hye Lim JANG ; Hee Suk PARK ; Hyun Jin SON ; Si Hyun BAE ; Jin Han KANG ; Dae Won JUN ; Jin Woo LEE ; Young Jin HONG ; Young Seok KIM ; Chang Hwi KIM ; U Im CHANG ; Jong Hyun KIM ; Hyeon Woong YANG ; Hong Soo KIM ; Kyeong Bae PARK ; Jae Seok HWANG ; Jeong HEO ; In Hee KIM ; Jung Soo KIM ; Gab Jin CHEON
Journal of Korean Medical Science 2013;28(6):908-914
This study aimed to identify the risk factors associated with acute hepatitis A virus (HAV) infection in the Korean population. Participants were recruited from five referral hospitals across the country in 2007 and from 11 hospitals in 2009. Patients with positive anti-HAV IgM antibody tests became the case group, while patients treated for non-contagious diseases at the same hospitals were recruited as controls. A total of 222 and 548 case-control pairs were studied in the 2007 and 2009 surveys, respectively. Data from the surveys were analyzed jointly. In a multivariate analysis, sharing the household with HAV-infected family members (OR, 6.32; 95% CI, 1.4-29.6), contact with other HAV-infected individuals (OR, 4.73; 95% CI, 2.4-9.4), overseas travel in 2007 (OR, 19.93; 95% CI, 2.3-174.4), consumption of raw shellfish (OR, 2.51; 95% CI, 1.8-3.5), drinking bottled water (OR, 1.64; 95% CI, 1.3-8.4), and occupation that involve handling food (OR, 3.30; 95% CI, 1.3-8.4) increased the risk of HAV infection. Avoiding contact with HAV-infected individuals and avoiding raw foods eating could help minimize the risk of hepatitis A infection. Immunization must be beneficial to individuals who handle food ingredients occupationally or travel overseas to HAV-endemic areas.
Acute Disease
;
Adolescent
;
Adult
;
Case-Control Studies
;
Child
;
Child, Preschool
;
Female
;
Food Handling
;
Hepatitis A/*diagnosis/etiology/prevention & control
;
Hepatitis A Antibodies/blood
;
Humans
;
Immunoglobulin M/blood
;
Infant
;
Infant, Newborn
;
Interviews as Topic
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Odds Ratio
;
Referral and Consultation
;
Risk Factors
;
Seafood
;
Travel
;
Vaccination
;
Young Adult